EBV-associated diseases: Current therapeutics and emerging technologies
EBV is a prevalent virus, infecting> 90% of the world's population. This is an oncogenic virus
that causes~ 200,000 cancer-related deaths annually. It is, in addition, a significant …
that causes~ 200,000 cancer-related deaths annually. It is, in addition, a significant …
Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors
JR Kerr - Journal of clinical pathology, 2019 - jcp.bmj.com
Epstein-Barr virus (EBV) is a ubiquitous human virus which infects almost all humans during
their lifetime and following the acute phase, persists for the remainder of the life of the …
their lifetime and following the acute phase, persists for the remainder of the life of the …
Targeting Epstein-Barr virus in nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is consistently associated with Epstein-Barr virus (EBV)
infection in regions in which it is endemic, including Southern China and Southeast Asia …
infection in regions in which it is endemic, including Southern China and Southeast Asia …
Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma
The lack of representative nasopharyngeal carcinoma (NPC) models has seriously
hampered research on EBV carcinogenesis and preclinical studies in NPC. Here we report …
hampered research on EBV carcinogenesis and preclinical studies in NPC. Here we report …
Suppression of cGAS-and RIG-I-mediated innate immune signaling by Epstein-Barr virus deubiquitinase BPLF1
WY Lui, A Bharti, NHM Wong, S Jangra… - PLoS …, 2023 - journals.plos.org
Epstein-Barr virus (EBV) has developed effective strategies to evade host innate immune
responses. Here we reported on mitigation of type I interferon (IFN) production by EBV …
responses. Here we reported on mitigation of type I interferon (IFN) production by EBV …
The biology of EBV infection in human epithelial cells
SW Tsao, CM Tsang, PS Pang, G Zhang… - Seminars in cancer …, 2012 - Elsevier
EBV-associated human malignancies may originate from B cells and epithelial cells. EBV
readily infects B cells in vitro and transforms them into proliferative lymphoblastoid cell lines …
readily infects B cells in vitro and transforms them into proliferative lymphoblastoid cell lines …
Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is a squamous carcinoma with apparent geographical
and racial distribution, mostly prevalent in East and Southeast Asia, particularly …
and racial distribution, mostly prevalent in East and Southeast Asia, particularly …
Treatment advances in EBV related lymphoproliferative diseases
K Lv, T Yin, M Yu, Z Chen, Y Zhou, F Li - Frontiers in Oncology, 2022 - frontiersin.org
Epstein Barr virus (EBV) can affect 90% of the human population. It can invade B
lymphocytes, T lymphocytes and natural killer cells of the host and remain in the host for life …
lymphocytes, T lymphocytes and natural killer cells of the host and remain in the host for life …
EBV-related lymphomas: new approaches to treatment
JA Kanakry, RF Ambinder - Current treatment options in oncology, 2013 - Springer
Opinion statement In the treatment of Epstein-Barr virus (EBV)-related lymphomas, there are
few therapies specifically targeted against the latent virus within these tumors; in most cases …
few therapies specifically targeted against the latent virus within these tumors; in most cases …
Inhibition of class I histone deacetylases by romidepsin potently induces E pstein‐B arr virus lytic cycle and mediates enhanced cell death with ganciclovir
KF Hui, AKL Cheung, CK Choi… - … journal of cancer, 2016 - Wiley Online Library
Pan‐histone deacetylase (HDAC) inhibitors, which inhibit 11 HDAC isoforms, are widely
used to induce Epstein‐Barr virus (EBV) lytic cycle in EBV‐associated cancers in vitro and in …
used to induce Epstein‐Barr virus (EBV) lytic cycle in EBV‐associated cancers in vitro and in …